Observational study finds resistin activates inflammasome pathway in patients with pulmonary hypertension — Evidence Review
Published in PLOS ONE, by researchers from Johns Hopkins Medicine, Johns Hopkins University School of Medicine
Researched by
— the AI search engine for science
Table of Contents
A new study finds that human resistin, a signaling protein, directly primes and activates the NLRP3 inflammasome in immune cells, promoting chronic inflammation—a mechanism confirmed in lung tissue from patients with pulmonary hypertension. Related research largely supports these findings, linking resistin to increased inflammatory cytokine production and implicating it in various chronic diseases (1, 3, 5). For more, see the original study in PLOS ONE.
- Previous studies demonstrate that human resistin stimulates pro-inflammatory cytokines via the NF-κB pathway and is elevated in chronic inflammatory states, suggesting a broader role in disease processes (1, 2, 3, 5).
- The new findings expand on the established association of resistin with metabolic and cardiovascular diseases by pinpointing its role in inflammasome activation within macrophages, a step critical to prolonged inflammation (1, 3, 5).
- Evidence from related work shows that inflammatory triggers such as high insulin and leptin can upregulate resistin and cytokine production, reinforcing the connection between metabolic states, resistin, and chronic inflammatory mechanisms (4, 5).
Study Overview and Key Findings
Chronic inflammation underlies many common diseases, yet the molecular initiators of persistent inflammatory signaling are not fully understood. This study, conducted by researchers at Johns Hopkins Medicine, addresses this knowledge gap by exploring how human resistin interacts with immune cells to drive inflammation, particularly focusing on the NLRP3 inflammasome pathway—a central node in immune-mediated tissue injury. By analyzing both laboratory models and lung tissue from patients with pulmonary hypertension, the research connects molecular findings to human disease, highlighting potential therapeutic targets.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | Johns Hopkins Medicine, Johns Hopkins University School of Medicine |
| Journal Name | PLOS ONE |
| Authors | Udeshika Kariyawasam, Winson Lam, John Skinner, Rituparna Chakrabarti, Andrea Cox, Paul M. Hassoun, Qing Lin, Roger A. Johns |
| Population | Lung tissue from patients with pulmonary hypertension |
| Methods | Observational Study |
| Outcome | Resistin's effect on NLRP3 inflammasome activation in macrophages |
| Results | Resistin activation of the inflammasome pathway was confirmed in patient lung tissue. |
Literature Review: Related Studies
To understand how these findings fit into the broader scientific context, we searched the Consensus paper database, which contains over 200 million research papers. The following search queries were used:
- resistin inflammasome chronic inflammation
- lung tissue inflammation mechanisms
- inflammation triggers patient studies
The table below summarizes key topics and findings from related studies:
| Topic | Key Findings |
|---|---|
| How does human resistin influence inflammatory signaling? | - Human resistin stimulates pro-inflammatory cytokines (TNF-α, IL-12, IL-6) in macrophages via NF-κB and is elevated in obesity, diabetes, and chronic inflammatory conditions (1, 3, 4, 5). - Resistin can induce its own expression through positive feedback, and its pro-inflammatory effects are blocked by NF-κB inhibition (1, 3). |
| What mechanisms drive chronic inflammation in lung tissue? | - Chronic lung diseases (e.g., COPD, pulmonary hypertension) feature persistent activation of macrophages, cytokine release, and inflammasome activity, with oxidative stress and impaired resolution as key factors (6, 7, 8, 9, 10). - Failure to resolve inflammation in the lung leads to tissue damage and progression of respiratory diseases (7, 10). |
| What triggers or modulates systemic inflammation in patients? | - Systemic inflammation is promoted by factors such as elevated resistin, metabolic hormones (insulin, leptin), and infection, and is linked to cardiovascular and metabolic diseases (2, 4, 5, 12, 13). - Markers of inflammation (e.g., neutrophil-lymphocyte ratio, cytokines) predict adverse outcomes in cardiovascular and psychiatric disease, and may be influenced by pre-existing conditions (12, 13, 14). |
How does human resistin influence inflammatory signaling?
The new study's identification of resistin as a key regulator of inflammasome activation aligns with previous research showing resistin's potent pro-inflammatory effects in immune cells. Earlier studies demonstrate that resistin upregulates cytokines such as TNF-α and IL-12 in macrophages via NF-κB, and its levels are elevated in metabolic and inflammatory diseases (1, 3, 5). The new findings build on this by specifying that resistin not only primes macrophages but also directly activates the NLRP3 inflammasome, providing a mechanistic link to chronic inflammation.
- Human resistin stimulates secretion of pro-inflammatory cytokines by macrophages, independent of its molecular conformation (1).
- The pro-inflammatory action of resistin involves NF-κB signaling and can be blocked by NF-κB inhibitors (1, 3).
- Resistin upregulates its own expression and accumulates in inflamed tissues, such as joints in rheumatoid arthritis (3).
- Increased resistin is associated with metabolic, cardiovascular, and inflammatory diseases, suggesting a broad impact (5).
What mechanisms drive chronic inflammation in lung tissue?
Chronic lung inflammation is characterized by persistent infiltration and activation of immune cells, including macrophages, and the release of cytokines and inflammatory mediators (6, 7, 8). The new study's demonstration of heightened resistin and inflammasome pathway activity in lung tissue from pulmonary hypertension patients is consistent with this understanding. The literature emphasizes that impaired resolution of inflammation leads to tissue injury and disease progression in the lung (7, 10).
- Chronic lung diseases involve sustained macrophage activation, cytokine release, and inflammasome signaling (6, 7, 8).
- Oxidative stress and failed resolution of inflammation contribute to tissue damage and chronic disease (6, 8).
- Removal of activated immune cells, especially granulocytes, is essential for resolving lung inflammation; failure results in persistent disease (10).
- The balance between inflammation and anti-inflammation is crucial for lung health (7).
What triggers or modulates systemic inflammation in patients?
Multiple studies indicate that systemic inflammation can be triggered or exacerbated by increased resistin, metabolic hormones, infection, and underlying disease states (2, 4, 5, 12, 13, 14). Elevated resistin is both a consequence and driver of inflammation, linking metabolic dysfunction with immune activation. Inflammatory markers predict outcomes in cardiovascular, metabolic, and psychiatric conditions (12, 13, 14).
- Inflammation and metabolic factors (e.g., insulin, leptin) increase resistin and cytokine production in immune cells (2, 4).
- Systemic inflammation is associated with poor outcomes in cardiovascular disease and surgery (5, 12, 13).
- Elevated inflammatory biomarkers (e.g., CRP, NLR) are linked to psychiatric symptoms and disease progression (14).
- Inflammatory cascades involving resistin may worsen insulin resistance, atherosclerosis, and hypertension (2, 5).
Future Research Questions
While the new study clarifies resistin's role in activating the NLRP3 inflammasome and contributing to chronic inflammation, several questions remain about how these findings translate to broader disease contexts and therapeutic interventions. Future research can address these gaps by exploring the clinical implications of targeting resistin, the applicability to other inflammatory diseases, and the interplay with metabolic factors.
| Research Question | Relevance |
|---|---|
| Does blocking resistin reduce disease severity in patients with pulmonary hypertension? | Understanding whether resistin inhibition improves clinical outcomes could inform new targeted therapies for pulmonary hypertension and related lung diseases (5, 8). |
| Is resistin-mediated inflammasome activation a universal mechanism in other chronic inflammatory diseases? | Investigating whether resistin has similar roles in diseases such as rheumatoid arthritis, diabetes, and cardiovascular disease could broaden therapeutic opportunities (3, 5). |
| How do metabolic factors such as insulin and leptin modulate resistin's pro-inflammatory effects? | Elucidating the interplay between metabolic and immune signals could help explain why inflammation is heightened in obesity and type 2 diabetes (2, 4, 5). |
| What are the downstream consequences of chronic NLRP3 inflammasome activation in lung tissue? | Identifying cellular and tissue-level outcomes of sustained inflammasome activation could guide interventions to prevent irreversible lung damage (6, 8, 10). |
| Can biomarkers of resistin and inflammasome activity predict response to anti-inflammatory therapies? | Developing predictive biomarkers may enable personalized treatment approaches and improve outcomes in patients with chronic inflammatory diseases (5, 12, 13). |